Ronald Asbury Andrews - 01 Jul 2021 Form 4 Insider Report for OncoCyte Corp (OCX)

Role: Chief Executive Officer, Director
Signature: /s/ Ronald Andrews
Issuer symbol: OCX
Transactions as of: 01 Jul 2021
Net transactions value: $0
Form type: 4
Filing time: 02 Jul 2021, 21:32:23 UTC
Previous filing: 02 Jul 2021
Next filing: 05 Aug 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OCX	Common Stock, no par value	Options Exercise	$0	+65,000	+33%	$0.000000	259,046	01 Jul 2021	Direct
transaction	OCX	Common Stock, no par value	Tax liability	$0	-15,834	-6.1%	$0.000000	243,212	01 Jul 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OCX	Restricted Stock Units	Options Exercise	$0	-65,000	-100%	$0.000000^*	0	01 Jul 2021	Common Shares	65,000	$0.000000	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 65,000 Restricted Stock Units.
F2	Restricted Stock Units vested on July 1, 2021.